By Chris Wack
Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer patients.
The stock hit its 52-week high of $3.08 earlier in the session, and is up more than 100% in the past 12 months.
The New York-based biopharmaceutical company said the trial showed 100% of participants met the primary efficacy endpoint, with significant skin improvement by six weeks. Additionally, 66% experienced reduced pain and itching, enhancing quality of life without needing to reduce EGFRi doses.
Hoth said this is a breakthrough as it avoids such dose reductions, which it says is a common solution to these skin issues.
The trial confirmed no adverse effects, highlighting HT-001's tolerability, said the company.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 07, 2025 10:40 ET (15:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。